8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                    FORM 8-K
                                 CURRENT REPORT


     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                  May 16, 2008
                -------------------------------------------------
                Date of Report (Date of earliest event reported):


                         ACCELR8 TECHNOLOGY CORPORATION
               --------------------------------------------------
               (Exact name of registrant as specified in charter)

             Colorado                      0-11485                84-1072256
             --------                      -------                ----------
   (State or other jurisdiction   (Commission File Number)      (IRS Employer
         of incorporation)                                   Identification No.)

              7000 North Broadway, Building 3-307, Denver, CO 80221
            --------------------------------------------------------
                    (Address of principal executive offices)

                                 (303) 863-8808
             ------------------------------------------------------
               Registrant's telephone number, including area code:

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)
[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)
[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))
[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))




Item 1.01 Entry into a Material Definitive Agreement.

     Effective May 16, 2008, Accelr8 Technology Corporation (the "Accelr8") and
Becton, Dickinson and Company ("BD") entered into a Research and Option
Agreement (the "Agreement").

     The Agreement provides for the establishment of a research program from the
date of the Agreement until October 31, 2009 whereby BD will fund certain
research work by Accelr8 relating to Accelr8's BACcel(TM) rapid pathogen
diagnostics platform (the "BACcel Platform"). The research program includes
mutually agreed upon milestones to support BD's product development planning.
Under the terms of the Agreement, in connection with the research program,
Accelr8 will receive certain periodic payments from BD between the date of the
Agreement and July 1, 2009.

     The Agreement also grants BD an option to acquire for an upfront payment an
exclusive license (the "Exclusive License") from Accelr8 for certain know-how
and patent rights relating to the BACcel Platform. The Exclusive License also
provides for the Company to receive royalty payments on worldwide sales. The
Exclusive License contains certain diligence requirements for BD to develop and
commercialize such products. If BD exercises the option but fails to meet
certain terms of the Exclusive License, Accelr8 has the option to convert the
Exclusive License to a non-exclusive license. If BD does not exercise the
Exclusive License Accelr8 will receive a non-exclusive license from BD for
certain intellectual property.

     Pursuant to the Agreement, from the date of the Agreement until October 31,
2009, Accelr8 agreed not to engage in or participate in any discussions or
negotiations with parties other than BD for the joint development of, licensing
of or intellectual property relating to the BACcel Platform.

     Unless earlier terminated pursuant to the terms of the Agreement, the
Agreement shall terminate upon the Exclusive License Agreement or the
non-exclusive license from BD to Accelr8 coming into effect.

     The foregoing is a summary of certain of the material terms of the
Agreement and the Exclusive License and does not purport to be complete.

Item 9.01   Financial Statements and Exhibits.

     Exhibit 99.1. Press Release dated May 20, 2008 regarding Research and
                   Option Agreement




SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.






Date:  May 21, 2008                    ACCELR8 TECHNOLOGY CORPORATION

                                       By: /s/ Thomas V. Geimer
                                       --------------------------------------
                                       Thomas V. Geimer, Chief Executive Officer

EX-99.1

Exhibit 99.1

Accelr8 and BD Sign Research and Licensing Option
Agreement for Commercializing Accelr8's
BACcel(a) Rapid Diagnostics Technology

DENVER, Colo., May 20, 2008 - Accelr8 Technology Corporation (AMEX: AXK)
announced today that it has signed an agreement with BD (Becton, Dickinson and
Company) with respect to Accelr8's BACcel(a) rapid pathogen diagnostics
platform. Under the agreement, BD will fund a research program at Accelr8
through September 30, 2009. The research program includes mutually agreed
milestones to support BD's product development planning. BD has the option,
during or at the conclusion of the research program, to exclusively license
Accelr8's intellectual property in the field of infectious diseases diagnostics.
Accelr8 would retain the right to commercialize its technology for other
applications.

The option, if exercised by BD, requires BD to pay an initial fee, as well as
running royalties on covered products. The license further contains certain
diligence requirements for BD to develop and commercialize such products. Under
the license, BD will fund and conduct all product development, manufacturing,
and marketing. This agreement follows a standstill agreement signed in December
2007. Since signing that agreement, Accelr8 placed research systems into two
premier research institutions, Denver Health Medical Canter and Washington
University in St. Louis (Barnes-Jewish Hospital). The two research centers have
been conducting independent studies that confirm and extend Accelr8's internal
research that the company presented at two leading scientific and medical
conferences in 2007.

"We are very pleased to enter into a formal relationship with BD to develop what
Accelr8 believes will be the next major advance in infectious diseases
diagnostics," said David Howson, Accelr8's president. "As industry leader in
clinical microbiology, BD brings the tremendous resources and experience needed
to introduce this potentially game-changing innovation to hospitals globally."

"We also believe that this relationship offers our shareholders the best
opportunity by avoiding the distraction, risk, and dilution of further
fundraising," Howson continued. "The relationship assures that we can continue
to focus on the core science and technology and collaborate with leading
research institutions to build the case for clinical acceptance."

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative
materials and instrumentation for advanced applications in medical
instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is
developing a rapid pathogen analysis and diagnostic platform, the BACcel(a)
system, based on its innovative surface coatings, assay processing, and
detection technologies. In addition, Accelr8 licenses certain of its proprietary
technology for use in applications outside of Accelr8's own products.